By Nascent Biotech Posted July 27, 2018 In BJCR-104(10) copy2018-07-272018-07-27http://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.pngNascent Biotechhttp://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.png200px200px 0 Recent PostsNascent Biotech Inc (OTCMKTS: NBIO) Steady Rise Northbound as Phase 1 Clinical Trials Progress for Pritumumab (PTB) Targeting GlioblastomaNascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain CancerNascent Biotech’s CEO Sean Carrick Featured in In-Depth Interview with Proactive InvestorsNascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody
